Nexalin rises on positive data for sleep disorder treatment device

Nexalin Technology

06/03/2024 14:10

** Shares of medical equipment maker Nexalin Technology
 NXL.O  rise 15% to 40 cents premarket    
    ** Co says its experimental device to treat chronic insomnia
significantly reduced the severity of insomnia and enhanced
sleep quality and efficiency in adult patients      
    ** The device, Gen-2 tACS, was tested in 120 adult patients
ranging from 22 to 65 years old
     ** Chronic insomnia is characterized by difficulty in
initiating or maintaining sleep and early morning awakening,
occurring at least three nights per week for at least three
months
    ** NXL says patients aged 50 and over experienced
comparatively more significant benefits from tACS relative to
younger patients
    ** Up to last close, stock down ~64% in the last 12 months 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))